$INDP Here is what I liked about the stock online and the chart seemed to be indicating stock price has dipped from September but looks ready to bounce.
The big impetus for INDP’s 2023 rise appears to be the start of a Phase 1 clinical trial for its lead candidate, Decoy20, in December 2022, and the first patient dosing in March 2023.
The company had been sitting on dozens of issued or granted patents based on tech developed by Indaptus founder and chief scientific officer, Dr. Michael Newman, at Indaptus’ predecessor company, Decoy Biosystems.
The rubber finally met the road in 2023, though, and investors are clearly liking what they’re seeing.
I looked into Decoy20 and found it unusually interesting, and it’s easy to see why investors see such promise in it.
Decoy20 was inspired by the observation that tumors sometimes regress in the presence of a bacterial infection. The theory is that the infection may activate the immune system in a way the cancer doesn’t.
But you obviously don’t want to infect cancer patients with bacteria that could cause them sustained sickness.
Enter Decoy20.
It contains “proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity.”
In layman’s speak, Decoy20 is a weakened bacteria that INDP theorizes will broadly activate the immune system while passing quickly from the system without making the patient too sick.
Theoretical immune reaction from Decoy20. Source: Indaptus website.
To date — and it’s still in the very early stages — the Phase 1 trial has borne that out.
Just last Tuesday, the company released interim data from the first group of patients to receive Decoy20. According to a company press release:
The interim data . . . demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20.
That last part is important because the idea is for Decoy20 to be in and out — to cause a sustained immune response but not a sustained bacterial infection.
This lends weight to what has until now just been theory. The company presented the data to the Society for Immunotherapy of Cancer just this past Saturday.
The big impetus for INDP’s 2023 rise appears to be the start of a Phase 1 clinical trial for its lead candidate, Decoy20, in December 2022, and the first patient dosing in March 2023.
The company had been sitting on dozens of issued or granted patents based on tech developed by Indaptus founder and chief scientific officer, Dr. Michael Newman, at Indaptus’ predecessor company, Decoy Biosystems.
The rubber finally met the road in 2023, though, and investors are clearly liking what they’re seeing.
I looked into Decoy20 and found it unusually interesting, and it’s easy to see why investors see such promise in it.
Decoy20 was inspired by the observation that tumors sometimes regress in the presence of a bacterial infection. The theory is that the infection may activate the immune system in a way the cancer doesn’t.
But you obviously don’t want to infect cancer patients with bacteria that could cause them sustained sickness.
Enter Decoy20.
It contains “proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity.”
In layman’s speak, Decoy20 is a weakened bacteria that INDP theorizes will broadly activate the immune system while passing quickly from the system without making the patient too sick.
Theoretical immune reaction from Decoy20. Source: Indaptus website.
To date — and it’s still in the very early stages — the Phase 1 trial has borne that out.
Just last Tuesday, the company released interim data from the first group of patients to receive Decoy20. According to a company press release:
The interim data . . . demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20.
That last part is important because the idea is for Decoy20 to be in and out — to cause a sustained immune response but not a sustained bacterial infection.
This lends weight to what has until now just been theory. The company presented the data to the Society for Immunotherapy of Cancer just this past Saturday.
